%0 Journal Article
%T The value of long noncoding RNA CASC2 as a biomarker of prognosis in carcinomas: a meta-analysis
%A Fangwei Li
%A Jian Wang
%A Limin Chai
%A Manxiang Li
%A Qianqian Zhang
%A Qingting Wang
%A Wenhua Shi
%A Xin Yan
%A Yanting Zhu
%J Journal of Cancer
%D 2018
%I Ivyspring International Publisher
%R 10.7150/jca.26458
%X Lnc RNA Cancer Susceptibility Candidate 2(CASC2) has been shown to be aberrantly expressed in multiple types of cancer and might serve as a prognosis biomarker. The present meta-analysis was conducted to investigate whether the expression of CASC2 was associated with prognosis or clinicopathological features in correlative cancers. A total of 11 studies with 765 cancer patients were included by searching the electronic databases, the results found a significant association between high expression of CASC2 and longer OS in cancer patients (HR=0.43, 95% CI: 0.33-0.55, P =0.000).In addition, a significant correlation was observed between high level of CASC2 and earlier TNM stage(OR = 0.30, 95% CI =0.21-0.43, P < 0.001), smaller tumor size(OR = 0.28, 95% CI =0.12-0.66, P =0.004), better tumor differentiation(OR = 0.42, 95% CI =0.27-0.66, P =0.0002). In conclusion, CASC2 can serve as a novel marker predicting the prognosis and clinicopathological features in various cancers.
%K CASC2
%K cancer
%K biomarker
%K prognosis
%K meta-analysis
%U http://www.jcancer.org/v09p3824.htm